Supplemental material
Future Oncology
Volume 17, 2021 - Issue 31
Research Article
Real-World Association of HER2/ERBB2 Concordance with Trastuzumab Clinical Benefit in Advanced Esophagogastric Cancer
Stacey M Stein1 Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT06510, USA
https://orcid.org/0000-0001-8970-9144View further author information
https://orcid.org/0000-0001-8970-9144View further author information, Jeremy Snider2 Flatiron Health, Inc., New York, NY10025, USACorrespondence[email protected]
https://orcid.org/0000-0002-2117-7038View further author information
https://orcid.org/0000-0002-2117-7038View further author information, , Rebecca A Miksad2 Flatiron Health, Inc., New York, NY10025, USAhttps://orcid.org/0000-0003-3194-5122View further author information
https://orcid.org/0000-0003-3194-5122View further author information, Brian M Alexander4 Foundation Medicine, Inc., Cambridge, MA02141, USAhttps://orcid.org/0000-0003-3903-9175View further author information
https://orcid.org/0000-0003-3903-9175View further author information, Emily Castellanos2 Flatiron Health, Inc., New York, NY10025, USAhttps://orcid.org/0000-0003-4391-0496View further author information
https://orcid.org/0000-0003-4391-0496View further author information, , Russell Madison4 Foundation Medicine, Inc., Cambridge, MA02141, USAhttps://orcid.org/0000-0002-7838-2526View further author information
https://orcid.org/0000-0002-7838-2526View further author information, Akshay Swaminathan2 Flatiron Health, Inc., New York, NY10025, USAhttps://orcid.org/0000-0003-3426-9289View further author information
https://orcid.org/0000-0003-3426-9289View further author information, & Margaret McCusker2 Flatiron Health, Inc., New York, NY10025, USAhttps://orcid.org/0000-0003-2812-0787View further author information
https://orcid.org/0000-0003-2812-0787View further author information show all